R&D activity follows its iter in submission to designed competent authority for AIC (marketing authorizations).
Status quo is:
|
Radiopharmaceutical |
Temporary commercial name1 |
Forecast |
|
|---|---|---|---|
| 18F-Fdg | Glucompet | AIFA | within 2009 |
| 124I | Iodopet | EMEA FDA |
2010 2009 |
| 18F Colina | Colinpet | EMEA | 2010 |
| 124I Betacit | Dopapet | EMEA | 2010 |
| 64Cu | Cuprimina | EMEA | 2010 |
1 : Because the registration procedures are ongoin
The other following molecules are in experimental research and development phase in vivo and in vitro in animal tissues:
- 124I-CURCUMINA
- 124I-MIBG
- 64Cu-ASPARAGINA
- 64Cu-ATSM
- 64Cu-DIFOSFINE
- 64Cu-OCTEOTRIDE
